$0.21
0.00 (-0.86%)
Open$0.22
Previous Close$0.21
Day High$0.22
Day Low$0.21
52W High$2.89
52W Low$0.19
Volume—
Avg Volume6.73M
Market Cap7.72M
P/E Ratio—
EPS$-3.93
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+10,540.3% upside
Current
$0.21
$0.21
Target
$22.10
$22.10
$15.13
$22.10 avg
$31.02
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.02M | 2.37M | 1.31M |
| Net Income | -320,660,983 | -337,695,863 | -292,011 |
| Profit Margin | -15,861.4% | -15,068.3% | -22.2% |
| EBITDA | -267,110,889 | -296,928,790 | -341,169 |
| Free Cash Flow | — | — | -173,511 |
| Rev Growth | -14.5% | -14.5% | +20.5% |
| Debt/Equity | — | — | 0.83 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |